Biotechnology · Wayne, Pennsylvania, United States
$144.76
-3.74% (-$5.63)2026-07-10
Smart-Money SignalNeutral · 51/100— Insiders are net sellers over 90 days (-$1.4M, 18 sales vs 10 buys)
Net Income-$11.3M
EPS$-2.63
Market Cap$1.7B
Price Performance
Historical data including institutional events
Company Profile
W
Wesley Kaupinen
CEO & Executive Director
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
